[I-131]-TYR3-octreotide: Clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors

Authors
Baulieu, JL Resche, I Bardies, M Chauvet, AF Lecloirec, J Malhaire, JP Thomas, E Faurous, P Sassolas, G Pourcelot, L Chatal, JF Guilloteau, D Besnard, JC
Citation
Jl. Baulieu et al., [I-131]-TYR3-octreotide: Clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors, NUCL MED BI, 27(8), 2000, pp. 809-813
Citations number
15
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
NUCLEAR MEDICINE AND BIOLOGY
ISSN journal
09698051 → ACNP
Volume
27
Issue
8
Year of publication
2000
Pages
809 - 813
Database
ISI
SICI code
0969-8051(200011)27:8<809:[CDAUF>2.0.ZU;2-Q
Abstract
Dosimetry and therapeutic application of [I-131] Tyr3-octreotide were evalu ated in three patients with metastatic paraganglioma and carcinoid tumor. T he in vitro stability of [I-131]-Tyr3-octreotide was verified. Tumor uptake and residence time were between 0.02 and 0.1% and 0.5 to 9.8 h, respective ly. The calculated tumor radiation doses were between 0.105 and 0.696 mGy.M Bq(-1). No intolerance or adverse effects were observed after the therapeut ic doses (3.3-6.6 GBq). A partial tumor response was obtained in one patien t and no response occurred in two patients, NUCL MED BIOL 27;8:809-813, 200 0. (C) 2000 Elsevier Science Inc. All rights reserved.